ANGO
ANGIODYNAMICS INC
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$11.39
+1.33%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 325.4M | 320.2M | 292.5M | 303.9M | 338.8M |
| Cost of Revenue | 144.3M | 145.3M | 134.8M | 149.2M | 164.5M |
| Gross Profit | 181.1M | 174.9M | 157.7M | 154.7M | 174.2M |
| Operating Expenses | |||||
| R&D Expense | 31.0M | 29.4M | 26.2M | 31.5M | 29.9M |
| SG&A Expense | 158.9M | 157.1M | 145.2M | 144.0M | 144.3M |
| General & Admin Expense | 43.6M | 43.7M | 42.1M | 41.2M | 40.0M |
| Selling & Marketing Expense | 115.3M | 113.4M | 103.1M | 102.8M | 104.2M |
| Other Expenses | 27.8M | 28.3M | 26.2M | 171.6M | 51.3M |
| Total Operating Expenses | 217.6M | 214.8M | 197.7M | 347.1M | 225.4M |
| Cost and Expenses | 362.0M | 360.1M | 332.5M | 496.3M | 389.9M |
| Operating Income (EBIT) | (36.6M) | (39.9M) | (40.0M) | (192.4M) | (51.2M) |
| Non-Operating | |||||
| Interest Income | — | — | 978.0K | 1.6M | — |
| Interest Expense | 383.0K | 299.0K | — | — | 2.7M |
| Net Interest Income | (383.0K) | (299.0K) | 978.0K | 1.6M | (2.7M) |
| Other Non-Op Income/Expense | 3.8M | 3.6M | 5.9M | 797.0K | (3.3M) |
| Non-Operating Income (excl Interest) | (4.2M) | (17.5M) | (15.9M) | (158.6M) | (32.5M) |
| EBT (Pre-Tax Income) | (32.8M) | (36.3M) | (34.0M) | (191.6M) | (54.4M) |
| Income Tax Expense | 178.0K | 442.0K | (39.0K) | (7.3M) | (2.0M) |
| Bottom Line | |||||
| Net Income | (32.9M) | (36.7M) | (34.0M) | (184.3M) | (52.4M) |
| Earnings from Cont. Ops | (32.9M) | (36.7M) | (34.0M) | (184.3M) | (52.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.9M) | (36.7M) | (34.0M) | (184.3M) | (52.4M) |
| Per Share | |||||
| Basic EPS | ($0.79) | ($0.88) | ($0.83) | ($4.59) | ($1.33) |
| Diluted EPS | ($0.79) | ($0.88) | ($0.83) | ($4.59) | ($1.33) |
| Revenue Per Share | $7.74 | $7.71 | $7.14 | $7.56 | $8.58 |
| Shares | |||||
| Basic Shares Outstanding | 42.0M | 41.5M | 41.0M | 40.2M | 39.5M |
| Diluted Shares Outstanding | 42.0M | 41.5M | 41.0M | 40.2M | 39.5M |
| Profitability Metrics | |||||
| EBITDA | (9.9M) | 488.0K | 1.7M | (6.1M) | 12.2M |
| D&A | 22.5M | 23.0M | 25.8M | 27.7M | 30.9M |
| EBIT | (32.4M) | (22.5M) | (24.1M) | (33.8M) | (18.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Aug 1, 2026